Ann Dermatol.  2016 Feb;28(1):74-79. 10.5021/ad.2016.28.1.74.

Association of Adipokines, Insulin Resistance, Hypertension and Dyslipidemia in Patients with Psoriasis Vulgaris

• Coban M
• Tasli L
• Turgut S
• Ozkan S
• Tunc Ata M
• Akin F

• KMID: 2429484
• DOI: http://doi.org/10.5021/ad.2016.28.1.74

Abstract

BACKGROUND
Systemic inflammation in psoriasis causes insulin resistance and cardiovascular diseases. Adipokines are adipose-tissue-derived factors that are involved in metabolic processes. It is thought that these adipokines are associated with the development of psoriasis.
OBJECTIVE
The purpose of this study was to determine the changes in adipokine levels, insulin resistance, hypertension, and dyslipidemia over a 12-week period.
METHODS
The study comprised 35 psoriasis patients and 50 controls. Blood samples were obtained twice from the patients, one sample at the start and one at the end of a 12-week follow-up period. The following parameters were assessed in both groups: serum fasting glucose, fasting insulin, homeostasis model assessment-estimated insulin resistance (HOMA-IR) index, serum lipids, adiponectin, leptin, resistin, chemerin, omentin, vaspin, visfatin, retinol-binding protein 4, and high-sensitivity C-reactive protein (hs-CRP) levels; blood pressure; body mass index; and the psoriasis area severity index (PASI) scores.
RESULTS
The patients showed an improvement in the PASI score and a significant decrease in serum hs-CRP, omentin, and chemerin values. Moreover, at the start of the follow-up, the psoriasis patients had significantly lower levels of adiponectin and visfatin and significantly higher levels of vaspin and resistin than those of the control group. Visfatin levels correlated negatively with low-density lipoprotein (LDL) and cholesterol, while vaspin and omentin levels correlated positively with diastolic blood pressure. Decreased adiponectin levels correlated negatively with diastolic blood pressure and LDL.
CONCLUSION
Plasma levels of adipokines might be useful for evaluating the disease activity of psoriasis and its comorbidities.

Keyword

Adipokines; C-reactive protein; Psoriasis

MeSH Terms

Adipokines*
Adiponectin
Blood Pressure
Body Mass Index
C-Reactive Protein
Cardiovascular Diseases
Cholesterol
Comorbidity
Dyslipidemias*
Fasting
Follow-Up Studies
Glucose
Homeostasis
Humans
Hypertension*
Inflammation
Insulin Resistance*
Insulin*
Leptin
Lipoproteins
Metabolism
Nicotinamide Phosphoribosyltransferase
Plasma
Psoriasis*
Resistin
Adipokines
Adiponectin
C-Reactive Protein
Cholesterol
Glucose
Insulin
Leptin
Lipoproteins
Nicotinamide Phosphoribosyltransferase
Resistin

Figure

• 

  Fig. 1 Follow-up, adiponectin, hs-CRP, leptin, resistin, visfatin levels of psoriasis patients before and after systemic methotrexate treatment. hs-CRP: high-sensitivity C-reactive protein.

• 

  Fig. 2 Follow-up, chemerin, omentin, RBP4, vaspin levels of psoriasis patients before and after systemic methotrexate treatment. RBP4: retinol-binding protein 4.

Reference

1. Rajappa M, Rathika S, Munisamy M, Chandrashekar L, Thappa DM. Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2015; 29:69–76.

2. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther. 2010; 23:114–118.

3. Mazlin MB, Chang CC, Baba R. Comorbidities associated with psoriasis - data from the malaysian psoriasis registry. Med J Malaysia. 2012; 67:518–521.

4. González-Gay MA, González-Vela C, González-Juanatey C. Psoriasis: a skin disease associated with increased cardiovascular risk. Actas Dermosifiliogr. 2012; 103:595–598.

5. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011; 25:1007–1011.

6. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011; 20:81–87.

7. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007; 157:1249–1251.

8. Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ. 2010; 340:b5666.

9. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296:1735–1741.

10. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20:303–307.

11. Gerkowicz A, Pietrzak A, Szepietowski JC, Radej S, Chodorowska G. Biochemical markers of psoriasis as a metabolic disease. Folia Histochem Cytobiol. 2012; 50:155–170.

12. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010; 24:1386–1394.

13. Karadag AS, Ertugrul DT, Kalkan G, Bilgili SG, Celik HT, Takci Z, et al. The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study. Dermatology. 2013; 227:103–108.

14. Romaní J, Caixàs A, Ceperuelo-Mallafré V, Carrascosa JM, Ribera M, Rigla M, et al. Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch Dermatol Res. 2013; 305:105–112.

15. Takahashi H, Tsuji H, Honma M, Ishida-Yamamoto A, Iizuka H. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res. 2013; 305:113–116.

16. Xue Y, Jiang L, Cheng Q, Chen H, Yu Y, Lin Y, et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One. 2012; 7:e46740.

17. Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol. 2013; 168:749–755.

18. Saalbach A, Vester K, Rall K, Tremel J, Anderegg U, Beck-Sickinger AG, et al. Vaspin--a link of obesity and psoriasis? Exp Dermatol. 2012; 21:309–312.

19. Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis. Exp Dermatol. 2012; 21:43–47.

20. Ismail SA, Mohamed SA. Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol. 2012; 167:436–439.

21. Ohtsuka T. The relation between high-sensitivity C-reactive protein and maximum body mass index in patients with psoriasis. Br J Dermatol. 2008; 158:1141–1143.

22. Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol. 2011; 36:845–850.

23. Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013; 169:1066–1070.

24. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol. 2004; 18:180–183.

25. Karadag AS, Yavuz B, Ertugrul DT, Akin KO, Yalcin AA, Deveci OS, et al. Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol. 2010; 49:642–646.

26. Ucak S, Ekmekci TR, Basat O, Koslu A, Altuntas Y. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol. 2006; 20:517–522.